WARF: P150057US02

Predicting Glucoregulatory Dysfunction


Dhanansayan Shanmuganayagam, Rozalyn Anderson, Ricki Colman, James Ntambi, Mary Lindstrom, Michael Polewski, Maggie Burhans

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a method for identifying individuals at risk for glucoregulatory dysfunction associated with metabolic syndrome, prediabetes or Type II (adult onset) diabetes.
OVERVIEWThe term glucoregulatory dysfunction covers a spectrum of disorders from insulin resistance to prediabetes and diabetes. Problems associated with glucoregulatory dysfunction and obesity dominate health care costs in the U.S. today.

The test used to identify glucoregulatory dysfunction (based on high blood glucose levels or glycosylated hemoglobin) works after the fact, i.e., it confirms the problem rather than initially detecting it. A better test, one that could be used to screen at-risk patients before they progress to a more serious condition, would enable earlier intervention and improved patient outcomes.
THE INVENTIONUW–Madison researchers have developed a method based on blood lipid chemistry to identify a subject at risk for glucoregulatory dysfunction. The method involves obtaining a biosample from the subject, separating the diacylglycerol fatty acids and determining if the concentration is above or below a control range.
  • Metabolic syndrome can almost double a person’s health care costs and accounts for $17 billion in lost productivity in the U.S.
  • Diagnostic test to screen individuals at risk for glucoregulatory dysfunction
  • Identifying those eligible for treatment and insurance reimbursement
  • Predicts a problem in advance of more serious conditions (e.g., prediabetes)
  • Can be easily and routinely administered
  • Opportunity for early intervention
STAGE OF DEVELOPMENTSuccessful animal studies have been performed.
For More Information About the Inventors
Contact Information
For current licensing status, please contact Rafael Diaz at or 608-960-9847.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.